Therapeutic Drug Monitoring to Spike to $2.69 Billion by 2019

Tuesday 16 April 2013, Amsterdam

This newly published “Therapeutic Drug Monitoring” report that therapeutic drug monitoring (TDM) will spike to $2.69 billion by 2019.
    
Therapeutic drug monitoring can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global therapeutic drug monitoring market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.

The “Therapeutic Drug Monitoring” report covers:

• Chemiluminescence
• High Pressure Liquid Chromatography (HPLC)
• Gas Chromatography/Mass Spectrometry
• Liquid Chromatography/Mass Spectrometry
• Flucytosine
• Triazoles
• Itraconazole
• Voriconazole
• Posaconazole
• Enzyme Immunoassays
• Enzyme Multiplied Immunoassay Technique
• Enzyme Donor Immunoassays
• Radio Immunoassays
• Fluorescence Polarization Immunoassays
• Lateral Flow Immunoassays
• Particle Enhanced Turbidimetric Inhibition Immunoassays
• Affinity Chrome Mediated Immunoassays

    
The “Therapeutic Drug Monitoring” report examines companies manufacturing therapeutic drug monitoring equipment and supplies in the world.

Companies covered include:

• Abaxis,
•  Abbott,
• Alere,
• Alfa Wassermann,
• AMS,
• Beckman Coulter,
• BioMerieux,
• Carolina Chemistries,
• DiaSorin,
• Grifols,
• Horiba,
• Medica,
• Nova Biomedical,
• Ortho Clinical Diagnostics,
• Polymedico,
• Randox,
•  Roche and Siemens.